The UK and US have finalized a key trade agreement that will ensure zero import taxes on UK pharmaceutical shipments entering the American market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to raise funding on medicines through the public health system. This commitment secures that tariffs on these key products will be held at nothing for a duration of 36 months.
This deal follows previous threats to dramatically increase tariffs on branded drug products, with potential rates floated up to one hundred percent.
"This deal with the United Kingdom strengthens the global environment for new treatments and brings much-needed equity to American-British drug exports," a statement said.
Economic Impact
Medicines constitute one of the Britain's most significant goods shipped to the America, which is clearly the primary buyer for large UK drugmakers.
Trade data indicate that in the 12 months to the end of last September, the UK sold pharmaceutical products valued at billions to the US. This amount made up 17.4% of British export trade in that timeframe.
"This guarantee safeguards employment, boosts capital expenditure and sets the stage for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The pact involves several specific changes from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to raise overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The amount manufacturers must return to the NHS to prevent overspending will be limited at 15%. Last year, repayments topped 20%.
Recent Tensions
The deal comes amid a ongoing dispute between the sector and the British authorities over spending levels and NHS adoption.
These tensions were heightened by assertions that American consumers were paying a premium for the identical medicines than consumers in the Britain and the EU.
Recently, several major drug company projects in the UK have been paused or scrapped, while multi-billion-dollar investments have been pledged toward American operations.
One official acknowledged that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the last ten years.
